Brokerages Expect Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) to Announce -$0.61 EPS

Brokerages forecast that Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) will post ($0.61) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Bellerophon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.62) and the highest estimate coming in at ($0.59). Bellerophon Therapeutics reported earnings of ($0.36) per share in the same quarter last year, which would indicate a negative year over year growth rate of 69.4%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($2.31) per share for the current year, with EPS estimates ranging from ($2.36) to ($2.26). For the next financial year, analysts expect that the firm will post earnings of ($1.96) per share, with EPS estimates ranging from ($2.84) to ($1.07). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that that provide coverage for Bellerophon Therapeutics.

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) last issued its earnings results on Wednesday, May 11th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04).

Several analysts have recently weighed in on BLPH shares. Brookline Capital Acquisition dropped their price target on shares of Bellerophon Therapeutics from $26.00 to $19.00 in a research note on Monday, April 4th. began coverage on Bellerophon Therapeutics in a research report on Saturday, May 21st. They issued a “sell” rating for the company. Finally, Brookline Capital Management reduced their target price on Bellerophon Therapeutics from $26.00 to $19.00 in a research report on Monday, April 4th.

Bellerophon Therapeutics stock traded up $0.10 during midday trading on Friday, hitting $1.04. 284 shares of the stock were exchanged, compared to its average volume of 55,428. The stock’s 50-day simple moving average is $1.68 and its 200 day simple moving average is $2.31. Bellerophon Therapeutics has a fifty-two week low of $0.67 and a fifty-two week high of $5.95. The stock has a market capitalization of $9.93 million, a price-to-earnings ratio of -0.55 and a beta of -0.17.

An institutional investor recently raised its position in Bellerophon Therapeutics stock. BlackRock Inc. increased its stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) by 3.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 120,620 shares of the biotechnology company’s stock after purchasing an additional 4,138 shares during the period. BlackRock Inc. owned approximately 1.27% of Bellerophon Therapeutics worth $490,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 12.93% of the company’s stock.

About Bellerophon Therapeutics (Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

See Also

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.